Showing posts with label Forbes. Show all posts
Showing posts with label Forbes. Show all posts

Friday, November 13, 2009

Forbes: Medicare Part D: A Health Care Success Story

Mary Grealy writes that among the pitfalls America has seen with Medicare, there may be one beacon of hope with Medicare Part D. Grealy says, the landmark legislation that created Part D was passed by Congress in 2003 with bipartisan support. It was the first major overhaul of Medicare in 35 years, and it offered a much-needed benefit to seniors struggling to pay for their prescriptions...Far from leaving seniors with limited options, Part D allows Medicare enrollees to choose the prescription plan that most closely aligns with their needs. In the Medicare Today survey, 80% of participants say their plan covers all the medicines their doctor prescribes. The numbers were even higher in New York and Florida.

To read more about the success of Medicaid Part D, please visit Grealy's article.

Medicare Part D: A Health Care Success Story




Wednesday, August 19, 2009

Baxter Loses Medicare Reimbursement Suit

This article in Forbes discusses how a US District Court has ruled against Baxter International Inc. stating that it is not entitled to a higher Medicare reimbursement price for its hemophilia drug Advate. Baxter has previously asked Medicare to reclassify the drug so that reimbursements would increase because according to Baxter its Medicare reimbursement prices were less than the drug's sale price. Medicare's reasoning for not reclassifying the drug was that Advate was put into the "multiple drug source" category because it reached the market in the summer of 2003, about two months before the change in regulations took place.

If you'd like to join a group of professionals in the MDRP field, join our Medicaid Drug Rebate Program LinkedIn Group!